|
Trial-in-progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merit Medical Systems |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi |
Speakers' Bureau - MSD Oncology |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche |
|
|
No Relationships to Disclose |